K

    Kalaris Therapeutics, Inc. (KLRS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.04
    +0.01 (+0.25%)

    Market Cap: $95.93M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    77%(20/26)
    Avg Surprise
    -212.01%
    Streak
    3 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.52
    Range$-0.58 - $-0.39
    8 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.56-8.9%
    60d ago$-0.53-1.9%
    30d ago$-0.52+0.0%
    7d ago$-0.52+0.0%
    Current$-0.52
    Revenue Consensus
    $0
    Range$0 - $0
    7 analysts
    Dec 31, 2026
    EPS Consensus$-0.47
    Range$-0.54 - $-0.31
    8 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.47---
    Sep 26EST
    		-$-0.52---
    Jun 26
    		$-0.48$-0.50+4.00%Beat+21.3%
    Mar 26
    		$-0.46$-0.52+11.54%Beat+81.7%
    Dec 25
    		$-0.44$-0.55+20.00%Beat+86.6%
    Sep 25
    		$-0.64$-0.61-4.92%Miss+22.2%
    Jun 25
    		$-0.61$-0.52-17.31%Miss-1120.0%
    Mar 25
    		$-2.52$-0.77-227.27%Miss-869.2%
    Dec 24
    		$-3.28$-0.12-2633.33%Miss-530.8%
    Sep 24
    		$-0.82$-0.10-765.58%Miss-110.8%
    Jun 24
    		$-0.05$-0.05+0.00%Beat+89.6%
    Mar 24
    		$-0.26$-0.26+0.00%Beat+40.9%
    Dec 23
    		$-0.52$-0.52+0.00%Beat-62.5%
    Sep 23
    		$-0.39$-0.39+0.00%Beat+22.0%
    Jun 23
    		$-0.48$-0.48+0.00%Beat+30.4%
    Mar 23
    		$-0.44$-0.47+6.38%Beat+36.2%
    Dec 22
    		$-0.32$-0.32+0.00%Beat+65.2%
    Sep 22
    		$-0.50$-0.50+0.00%Beat+30.6%
    Jun 22
    		$-0.69$-0.69+0.00%Beat-15.0%
    Mar 22
    		$-0.69$-0.69+0.00%Beat-38.0%
    Dec 21
    		$-0.92$-0.92+0.00%Beat-124.4%
    Sep 21
    		$-0.72$-0.72+0.00%Beat-24.1%
    Jun 21
    		$-0.60$-0.60+0.00%Beat-76.5%
    Mar 21
    		$-0.50$-0.50+0.00%Beat+88.1%
    Dec 20
    		$-0.41$-0.44+6.82%Beat-
    Sep 20
    		$-0.58$-0.58+0.00%Beat-
    Jun 20
    		$-0.34N/A+92.33%Beat-
    Mar 20
    		$-4.21$-0.20-2005.00%Miss-

    Key Metrics

    Valuation
    P/E Ratio-2.00EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-79.90%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio10.98xQuick Ratio10.98x
    Trading Statistics
    BetaN/AAvg Volume57.11K
    52-Week High$11.8852-Week Low$3.03

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$4.10
    SMA 20$4.08
    SMA 50$4.16
    SMA 200$6.46
    EMA 10$4.07
    EMA 20$4.06
    EMA 50$4.25
    EMA 200$5.50

    MACD

    Line: -0.01Signal: -0.02Hist: 0.01

    ADX

    ADX: 16.0+DI: 18.2-DI: 14.7

    Aroon & PSAR

    Aroon Up24.0
    Aroon Down12.0
    PSAR$3.47

    Bollinger Bands

    Upper Band$4.30
    Lower Band$3.86
    %B Position1065%(Upper)
    Band Width0.41

    RSI (14-Day)

    Neutral
    48.4

    Momentum Oscillators

    Stoch %K44.6
    Stoch %D50.0
    Williams %R-58.0
    ROC (10d)2.0%
    Momentum0.08
    CCI (20d)-105.2
    MFI (14d)44.2

    Volatility Measures

    ATR (14d)$0.30(7.4%)
    StdDev (20d)0.11
    Hist Vol44.1%(High)

    Volume Flow

    VWAP$3.97
    OBV1.5M
    AD Line-18.7M
    CMF (20d)-0.057

    Volume Metrics

    Avg Vol (20d)52.1K
    Vol Ratio0.4x(Low)
    VWMA (20d)$4.10

    Pivot Points

    R3$4.42
    R2$4.28
    R1$4.16
    Pivot Point$4.02
    S1$3.90
    S2$3.76
    S3$3.64

    Advanced Oscillators

    TSI-0.99
    Ultimate Osc54.4
    KST11.45

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0$0
    Cost of Revenue$0$0$10,000$0$0$0N/A$0$0$0N/A$0
    Gross Profit$0$0$-10,000$0$0$0N/A$0$0$0N/A$0
    Operating Expenses$12.39M$11.83M$10.80M$12.74M$12.26M$10.35M$7.13M$37.85M$4.19M$2.56M$62.41M$46.96M
    R&D$9.02M$7.57M$7.16M$9.13M$8.44M$6.03M$3.85M$36.02M$3.21M$1.96M$33.37M$34.16M
    SG&A$3.37M$4.26M$3.64M$3.62M$3.82M$4.32M$3.28M$1.83M$976,000$602,000$10.46M$12.80M
    Operating Income$-12,386,000$-11,833,000$-10,801,000$-12,741,000$-12,256,000$-10,354,000$-7,133,000$-37,849,000$-4,187,000$-2,563,000$-62,405,000$-46,961,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$1.37M$1.52M
    Interest Expense$0$0$0$0$0$0$1.31M$815,000$499,000$78,000$0$0
    Income Before Tax$-11,515,000$-10,856,000$-9,998,000$-11,894,000$-11,350,000$-10,161,000$-22,026,000$-38,084,000$-5,650,000$-3,407,000$-59,822,000$-44,272,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-11,515,000$-10,856,000$-9,998,000$-11,894,000$-11,350,000$-10,196,000$-22,026,000$-38,084,000$-5,650,000$-3,407,000$-59,696,000$-44,272,000
    EBITDA$-11,619,000$-11,066,000$-10,304,000$-11,894,000$-11,350,000$-10,161,000$-20,717,000$-37,269,000$-5,151,000$-3,329,000$-62,264,000$-46,941,000
    EBIT$-11,515,000$-10,856,000$-9,998,000$-11,894,000$-11,350,000$-10,161,000$-20,717,000$-37,269,000$-5,151,000$-3,329,000$-61,193,000$-45,794,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about KLRS

    News

    Kalaris Therapeutics Reports Q2 Financial Results, Advances Clinical Program

    Kalaris Therapeutics announced its Q2 2026 financial results, reporting $93.5 million in cash, cash equivalents, and marketable securities, projected to fund operations into Q4 2027. The company is advancing its phase 1b/2 study of TH103 for neovascular age-related macular degeneration (AMD), with preliminary data expected in H1 2027. Kalaris also appointed Liisa Bayko as chief financial officer to support its ongoing clinical program.

    VisionMonday.com•8/13/26•
    Neutral

    Kalaris Therapeutics, Inc. 2Q 2026: Net loss $(11.5M), Diluted EPS $(0.48) — 10-Q Summary

    Kalaris Therapeutics, Inc. reported a net loss of $(11.5M) for 2Q 2026, which was essentially flat compared to the previous year, while diluted loss per share improved to $(0.48). The company has no product revenue, with results primarily driven by research and development, and general and administrative expenses. Key business highlights include progress in clinical trials for TH103, pipeline expansion plans for nAMD, DME, DR, and RVO, and improvements in manufacturing processes.

    TradingView•8/12/26•
    Neutral

    Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates

    Kalaris Therapeutics announced its Q2 2026 financial results, including $93.5 million in cash expected to fund operations into Q4 2027. The company is currently dosing patients in a Phase 1b/2 study for TH103, a treatment for neovascular Age-related Macular Degeneration, with preliminary data anticipated in the first half of 2027. Kalaris also expanded its leadership team with a new CFO and board member.

    The Manila Times•8/11/26•
    Somewhat-Bullish

    Kalaris Therapeutics Releases Q2 2026 Financial Results

    Kalaris Therapeutics, Inc. (ALVR) reported a narrower loss for the second quarter of 2026, with a loss of $0.48 per share, improving 21.3% from the previous year. The company's net loss for the quarter was $11.5M, reflecting ongoing efforts to manage operating expenses while advancing its therapeutic pipeline and controlling its cash burn rate.

    AlphaStreet•8/11/26•
    Neutral

    Form 8K Kalaris Therapeutics Inc For: 11 August By Investing.com

    The article reports that Kalaris Therapeutics Inc. filed a Form 8K on August 11, according to Investing.com. This filing is a significant event for the company, as 8K forms are used to announce unscheduled material events or corporate changes important to investors. The article briefly mentions the company's stock symbol KLRS and its performance, showing a slight increase of 0.76%.

    Investing.com Canada•8/11/26•
    Neutral

    Frequently Asked Questions About KLRS

    Does KLRS pay dividends?
    Kalaris Therapeutics, Inc. (KLRS) does not currently pay a regular dividend.
    What is KLRS's market cap?
    Kalaris Therapeutics, Inc. (KLRS) has a market capitalization of $95.93M with a current stock price of $4.04.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In